AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Joint venture wins $11M award to expedite production of botulinum vaccine.
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- Computer Sciences Corporation (CSC) announced that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International, Inc., has been awarded an $11 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health, for fast-track development of a heptavalent botulinum vaccine.
Under this award, DVC plans to develop the manufacturing processes for a safe and efficacious vaccine that will protect against all known forms of botulinum neurotoxins within 5 years. These processes would then be available for transition into pilot lot manufacture of the vaccine prior to phase I clinical testing.
"Botulinum neurotoxin is generally recognized as the deadliest naturally occurring substance known and has been identified as a potential bioweapon," said DVC president Terry Irgens. "There is an urgent need for a safe, efficacious vaccine that will protect against all seven known serotypes of the neurotoxin."
The NIAID award funds ...
- CSC - Porton Joint Venture Wins $11 Million Award to Expedite Production of...
- Press release article from: PR Newswire September 4, 2003 700+ words
...National Institute of Allergy and Infectious Diseases (NIAID), a component of the National...track development of a heptavalent botulinum vaccine. Under this award, DVC plans to...Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Md...
- Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of...
- Press release article from: Business Wire July 24, 2008 700+ words
...Company's Botulinum Vaccine Program ROCKVILLE...Allergy and Infectious Diseases (NIAID...recombinant botulinum vaccine. This is...provide a botulinum vaccine designed...products target infectious diseases and other...
- Joint venture wins $11M award to expedite production of botulinum vaccine.
- Newspaper article from: Virus Weekly September 30, 2003 700+ words
...National Institute of Allergy and Infectious Diseases (NIAID), a component of the U...track development of a heptavalent botulinum vaccine. Under this award, DVC plans to...Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland...
- Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of...
- News wire article from: Bioterrorism Week August 11, 2008 700+ words
...Institute of Allergy and Infectious Diseases (NIAID) to fund the...serotype A and B recombinant botulinum vaccine. This is the first grant...BioSolutions has received for its botulinum vaccine program, and such support...Emergent's recombinant botulinum vaccine is ...
- U.S. firm to develop new botulinum vaccine.
- Newspaper article from: Health & Medicine Week September 29, 2003 700+ words
...spokeswoman for the U.S. Army Medical Institute of Infectious Diseases. "It basically employs a newer technique" for developing...Corp., is from the National Institute of Allergy and Infectious Diseases, a division of the U.S. National Institutes of Health...
- DOR BioPharma and Dowpharma Complete Feasibility Study for Production of...
- Press release article from: Business Wire November 17, 2005 700+ words
...three recombinant heavy chain botulinum fragments used in the development of BT-VACC(TM), DOR's proprietary mucosal botulinum vaccine. BT-VACC(TM) is designed to protect against botulinum toxin poisoning, one of the top three bioterrorism threats...
- George A. Robertson, Ph.D. Joins DOR BioPharma as Vice President of Research...
- Press release article from: Business Wire March 11, 2005 700+ words
MIAMI -- DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR) announced today the appointment of George A. Robertson, Ph.D. as the Company's Vice President of Research and Development. Dr. Robertson brings to DOR over 20 years of experience in the pharmaceutical, biopharmaceutical and biodefense
- Emerging infectious diseases: a 10-year perspective from the National Institute...
- Magazine article from: Emerging Infectious Diseases Fauci, Anthony S. Touchette, Nancy A. Folkers, Gregory K. April 1, 2005 700+ words
...and even deliberately disseminated infectious diseases (e.g., anthrax bioterrorism...National Institute of Allergy and Infectious Diseases (NIAID) have contributed substantially...extraordinary speed. ********** Infectious diseases have been an ever-present threat...
